Elise A. Chong, MD
Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Headshot of Elise A. Chong, MD
Penn Medicine Provider

About me

  • Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System

What my patients think about me

Average Rating

278 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
February 2026
Dr. Chong listens to me and takes her time explaining things. she's so very kind and personable.
Anonymous
February 2026
just all went well and have been seeing this doctor for 5 years.
Anonymous
January 2026
very knowledgeable and very thorough.
Anonymous
January 2026
she is very caring

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Chong is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Chong EA, Tomasulo EB, Barta SK. 2026 Update on the Management of Diffuse Large B-Cell Lymphoma , Am J Hematol, 101(4): 2026,832-863


Landsburg DJ, Musoke N, Gentile C, Brooks TR, Nasta SD, Barta SK, Carter JS, Chong EA, Svoboda J, Schuster SJ, Thomas CJ, Tomasulo EB, Cook MR, Morrissette JJD, Caimi PF, Hill BT. Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma , Leukemia, 40(3): 2026,694-697


Jiang C, Hoover T, Baron J, Han X, Li B, Gao Y, Kim M, Hubbeling H, Chong EA, Carter J, Svoboda J, Schuster SJ, Landsburg DJ, Nasta SD, Plastaras J, LaRiviere M. Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma. , Int J Part Ther, 19: 2026,101304


Shan Liu; Puneeth Guruprasad; Ranjani Ramasubramanian; Bhoomi Madhu; Luca Paruzzo; Kecheng Han; Andre Kelly; Alexander Shestov; He N Xu; Alberto Carturan; Chaoting Zhou; Kevin R Amses; Amichay Afriat; Lev Litichevskiy; Jason Lin; Ezra Dubowitz; Neil Tangal; Jing Zhang; Alana McSween; Melody Tan; Federico Stella; Andrew Lee; Siena Nason; Xianxin Hua; Michael Schneider; Madeleine Sleeman; Yunlin Zhang; Giulia Gabrielli; Ziqi Yang; Raymone Pajarillo; Ruchi Patel; Guido Ghilardi; Vrutti Patel; Akshita Joshi; Shunzhou Jiang; Yanqing Jiang; Patrizia Porazzi; Julia C Tchou; Brian Keith; Mingyao Li; Elise Chong; Stephen J Schuster; Michael Milone; Joshua Rabinowitz; Roderick O’Connor; Christoph A Thaiss; Maayan Levy; Marco Ruella β-Hydroxybutyrate Enhances the Metabolic Fitness of CAR T Cells in Cancer , Cell: 2026


Nikita Dave, Alexandra Dreyfuss, Alison Moskowitz, Joachim Yahalom, Maria Alfaro, Nicole Birrer, Boyu Hu, Rachel Koch, Zachary Frosch, Meryl Colton, Carrie Ho, Behzad Amoozgar, Tatyana Feldman, Abhiraj Saxena, Joanna Rhodes, Ashley Dunton, Nirav Shah, Amelia Mantione, Harper Hubbeling, Michael Lariviere, John Plastaras, Stefan Barta, Jordan Carter, Elise Chong, Michael Cook, Daniel Landsburg, Sunita Dwivedy Nasta, Stephen Schuster, Colin Thomas, Emily Tomasulo, Jakub Svoboda A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study , Blood, 146(Supplement 1): 2025,3617


Luca Paruzzo, Riemke Bouvier, Bria Fulmer, Ivan Cohen, Elise Chong, Jakub Svoboda, Sunita Dwivedy Nasta, Daniel Landsburg, Vrutti Patel, Matthew Ho, Alberto Carturan, Federico Stella, Adam Waxman, Adam Cohen, Dan Vogl, Stefan Barta, Audrey Bochi-Layec, Patrizia Porazzi, Joseph Fraietta, Alfred Garfall, Vijay Bhoj, Edward Stadtmauer, David Porter, James Riley, Peter Merkel, Stephen Schuster, Jordan Carter, Sokratis Apostolidis, Sandra Susanibar-Adaniya, Marco Ruella Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease , Blood, 146(Supplement 1): 2025,4543


Matthew Frank, David Qualls, Armin Ghobadi, Jordan Gauthier, Michael Tees, Luke Mountjoy, Joseph McGuirk, Sattva Neelapu, Reem Karmali, Iris Isufi, Brian Hill, Craig Sauter, Catherine Diefenbach, Jay Spiegel, Lizamarie Bachier-Rodriguez, Monalisa Ghosh, Nirav Shah, Rahul Lakhotia, Francisco Hernandez-Ilizaliturri, Anuja Abhyankar, Elise Chong, Matthew Schwede, Krish Patel, Olalekan Oluwole, John Baird, Nathan Denlinger, Farrukh Awan, Michael Jain, John Timmerman, Cesar Sanchez, Muthu Kumaran, Jean Yared, Jon Arnason, Ishan Tatake, Usama Gergis, Peter Riedell, Keith Pratz, Nirali Shah Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial) , Blood, 146(Supplement 1): 2025,667


Elise Chong, Rachel Lundberg, Matthew Lunning, Stefan Barta, Jordan Carter, Michael Cook, Joseph Fraietta, Daniel Landsburg, Hwan Lee, Sunita Dwivedy Nasta, Jakub Svoboda, Colin Thomas, Christopher D'Angelo, Robert Bociek, Megan Jones, Kaitlin Kennard, Brittany Koch, Peter Michener, Allison Nelson, Alvaro Ordonez, Luca Paruzzo, Marco Ruella, Mark Sellmyer, Ellen Napier, Emeline Chong, Stephen Schuster Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas , Blood, 146(Supplement 1): 2025,1952


Eliza Hawkes, Joanna Romejko-Jarosinska, Wojciech Jurczak, Sunil Iyengar, Abel Costa, Nimish Shah, Monique Menzies Wojtowicz, Allison Winter, Adam Witkowski, Neil Chua, Ana Jiménez Ubieto, John Kuruvilla, Diego Villa, Chan Cheah, Andre Goy, Elise Chong, Andrew Wood, Rachel Fletcher, Stefanie Meyer, Rebecca Silva, Simon Rule, Michael Wang Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study , Blood, 146(Supplement 1): 2025,884


Nikita Dave, Shannon Gier, Marni Kessler, Miguel Rodriguez, Stefan Barta, Elise Chong, Adam Cohen, Noelle Frey, Saar Gill, Shannon Heck, Elizabeth Hexner, Nasheed Hossain, Shivani Kapur, Daniel Landsburg, Alison Loren, Selina Luger, Mary Ellen Martin, Pashna Munshi, Sunita Dwivedy Nasta, Alexander Perl, David Porter, Stephen Schuster, Edward Stadtmauer, Sandra Susanibar-Adaniya, Jakub Svoboda, Abby Togliatii, Dan Vogl, Adam Waxman, Daniel Wu, Shannon McCurdy Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study , Blood, 146(Supplement 1): 2025,7189